Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02938572 | A Randomised Proof-of-Principle Trial Investigating Pharmacodynamics, Pharmacokinetics, and Safety of NNC0143-0406 in Subjects With Type 1 Diabetes Mellitus | PHASE1 | COMPLETED | 47 | — | — | Oct 19, 2016 | Jul 4, 2017 | Feb 26, 2018 | 1 | Austria |
| NCT02612844 | A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0143-0406 A 0.6 mmol/L in Subjects With Type 1 Diabetes | PHASE1 | COMPLETED | 48 | — | — | Nov 1, 2015 | Jun 1, 2016 | Dec 6, 2017 | 1 | Austria |
| Arm | Type | Description |
|---|---|---|
| NNC0143-0406 | EXPERIMENTAL | - |
| Insulin aspart | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| NNC0143-0406 | DRUG | Administered subcutaneously (s.c. under the skin) |
| Insulin Aspart | DRUG | Administered subcutaneously (s.c. under the skin) |
Inclusion Criteria: * Male or female aged 18-55 years (both inclusive) at the time of signing informed consent * Subjects diagnosed (clinically) with type 1 diabetes mellitus at least 365 days prior to the day of screening * Treated with continuous subcutaneous insulin infusion at least 90 days pri...